Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methylglutaconyl-CoA hydratase, mitochondrial (AUH), is a bifunctional mitochondrial enzyme encoded by the AUH gene. It catalyzes a key step (the hydration of 3-methylglutaconyl-CoA to 3-hydroxy-3-methylglutaryl-CoA) in the catabolism of the amino acid leucine[1][4][5][7]. Uniquely, AUH can also bind AU-rich RNA elements found in the 3' untranslated regions of certain mRNAs, linking mitochondrial metabolism and post-transcriptional gene regulation[3][5]. Loss of AUH function leads to 3-methylglutaconic aciduria type I, a rare autosomal recessive disease characterized by the accumulation of organic acids and neurological problems due to defective mitochondrial leucine breakdown[4][7]. AUH is important for mitochondrial RNA metabolism, protein synthesis, and overall mitochondrial morphology and function[1][6]. There are no known drugs that directly target AUH, and it is not currently considered a direct therapeutic target in drug development, but it is important in the pathology of certain metabolic disorders[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methylglutaconyl-CoA hydratase, mitochondrial (AUH).